We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Charles River Laboratories International Inc | NYSE:CRL | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-2.80 | -1.20% | 229.89 | 233.85 | 225.74 | 233.85 | 409,225 | 01:00:00 |
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
OMB APPROVAL
OMB Number: 3235-0287 Estimated average burden hours per response... 0.5 |
|
|
|
1. Name and Address of Reporting Person
*
MASSARO GEORGE |
2. Issuer Name
and
Ticker or Trading Symbol
CHARLES RIVER LABORATORIES INTERNATIONAL INC [ CRL ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__ X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) |
251 BALLARDVALE STREET |
3. Date of Earliest Transaction
(MM/DD/YYYY)
|
|
WILMINGTON, MA 01887 |
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |
||||||||||
1.Title of Security
(Instr. 3) |
2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 7/17/2017 | M | 4030 | A | $43.39 | 18731 | D | |||
Common Stock | 7/17/2017 | S (1) | 100 | D | $100.26 | 18631 | D | |||
Common Stock | 7/17/2017 | S (1) | 100 | D | $100.46 | 18531 | D | |||
Common Stock | 7/17/2017 | S (1) | 100 | D | $100.52 | 18431 | D | |||
Common Stock | 7/17/2017 | S (1) | 100 | D | $100.54 | 18331 | D | |||
Common Stock | 7/17/2017 | S (1) | 100 | D | $100.59 | 18231 | D | |||
Common Stock | 7/17/2017 | S (1) | 1 | D | $100.61 | 18230 | D | |||
Common Stock | 7/17/2017 | S (1) | 100 | D | $100.63 | 18130 | D | |||
Common Stock | 7/17/2017 | S (1) | 100 | D | $100.64 | 18030 | D | |||
Common Stock | 7/17/2017 | S (1) | 200 | D | $100.65 | 17830 | D | |||
Common Stock | 7/17/2017 | S (1) | 224 | D | $100.67 | 17606 | D | |||
Common Stock | 7/17/2017 | S (1) | 95 | D | $100.70 | 17511 | D | |||
Common Stock | 7/17/2017 | S (1) | 100 | D | $100.71 | 17411 | D | |||
Common Stock | 7/17/2017 | S (1) | 10 | D | $100.72 | 17401 | D | |||
Common Stock | 7/17/2017 | S (1) | 200 | D | $100.78 | 17201 | D | |||
Common Stock | 7/17/2017 | S (1) | 200 | D | $100.80 | 17001 | D | |||
Common Stock | 7/17/2017 | S (1) | 100 | D | $100.81 | 16901 | D | |||
Common Stock | 7/17/2017 | S (1) | 200 | D | $100.82 | 16701 | D | |||
Common Stock | 7/17/2017 | S (1) | 100 | D | $100.84 | 16601 | D | |||
Common Stock | 7/17/2017 | S (1) | 100 | D | $100.85 | 16501 | D | |||
Common Stock | 7/17/2017 | S (1) | 200 | D | $100.87 | 16301 | D | |||
Common Stock | 7/17/2017 | S (1) | 300 | D | $100.89 | 16001 | D | |||
Common Stock | 7/17/2017 | S (1) | 100 | D | $100.91 | 15901 | D | |||
Common Stock | 7/17/2017 | S (1) | 100 | D | $100.92 | 15801 | D | |||
Common Stock | 7/17/2017 | S (1) | 100 | D | $100.93 | 15701 | D | |||
Common Stock | 7/17/2017 | S (1) | 100 | D | $100.96 | 15601 | D | |||
Common Stock | 7/17/2017 | S (1) | 200 | D | $100.97 | 15401 | D | |||
Common Stock | 7/17/2017 | S (1) | 100 | D | $101.00 | 15301 | D | |||
Common Stock | 7/17/2017 | S (1) | 300 | D | $101.15 | 15001 | D | |||
Common Stock | 7/17/2017 | S (1) | 100 | D | $101.32 | 14901 | D |
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) |
|||||||||||||||
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Stock Options (Right to Buy) | $43.39 | 7/17/2017 | M | 4030 | 5/8/2014 | 5/8/2020 | Common Stock | 4030 | $0 | 0 | D |
Explanation of Responses: | |
(1) | This sale occurred pursuant to a 10b5-1 Trading Plan. |
Reporting Owners
|
|||||
Reporting Owner Name / Address |
|
||||
Director | 10% Owner | Officer | Other | ||
MASSARO GEORGE
251 BALLARDVALE STREET WILMINGTON, MA 01887 |
X |
|
|
|
Signatures
|
||
/s/ George E. Massaro | 7/18/2017 | |
** Signature of Reporting Person |
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year Charles River Laboratories Chart |
1 Month Charles River Laboratories Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions